TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05216653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2，ivgtt，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2，po，bid，d1-14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Radiation
Description: Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery, total mesorectal excision
Description: The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
Study: NCT06165172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoRegulator®
Description: Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
Study: NCT05788146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: A psychological intervention used to target depression
Study: NCT05232630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks.
Study: NCT05132686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IER+MED
Description: Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MED/DER
Description: Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
Study: NCT05819541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Granules
Description: Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
Study: NCT06750120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal weight counseling
Description: Counseling on health gestational weight gain and post partum weight loss

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost.
Study: NCT04811313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal epidural block
Description: regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
Study: NCT06750120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost.
Study: NCT06750952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab Combined With Chemotherapy
Description: Ivonescimab injection is an IgG1 subtype humanized bispecific antibody targeting human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1). It can bind to VEGF-A and PD-1 at the same time, and competitively block the interaction between VEGF-A, PD-1 and their ligands, exerting antitumor activity.
Study: NCT06749678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period. It includes the following strategies: (1) Exercise: Exercise should be carried out when the patient's condition allows, and the exercise programme should be dynamically adjusted according to the patient's tolerance, and it is advisable to maintain the Borg score between 11\~13 points (i.e., subjectively feel relaxed or a little strained). (2) Nutritional support: ensure that the patient's daily energy intake is 20\~25kcal/kg (the target energy reaches 30\~35kcal/kg), and the protein intake is 1.2\~1.5g/(kg·d). (3) Psychological intervention: for patients with mild to moderate anxiety or depression, health education, music therapy and other psychological interventions are carried out. For patients with severe anxiety or depression, psychologists will conduct psychological consultation for patients and provide professional psychological therapy.
Study: NCT04811313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal epidural block
Description: regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive standard care but neither TXA nor caudal epidural block
Study: NCT06749678

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine nursing measures
Description: Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine nursing measures
Description: Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.
Study: NCT04868864

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
Study: NCT05917249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capacitive-Resistive Noninvasive Radiofrequency
Description: The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
Study: NCT06494878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75-100 mg taken once daily by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: Low-molecular-weight heparin injections daily as prescribed by the treating physician.
Study: NCT04926194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual stromal cells (DSC)
Description: DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
Study: NCT05566587

Intervention type: OTHER
Group type: OTHER
Intervention: Mediteranean to Western to Mediteranean Diet
Description: week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet

Intervention type: OTHER
Group type: OTHER
Intervention: Mediteranean to Western to Mediteranean Diet
Description: week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet

Intervention type: OTHER
Group type: OTHER
Intervention: Western to Mediteranean to Western Diet
Description: week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet

Intervention type: OTHER
Group type: OTHER
Intervention: Western to Mediteranean to Western Diet
Description: week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
Study: NCT04991974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community.
Study: NCT05956691

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AllerPops
Description: Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AllerPops
Description: Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
Study: NCT06551649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood draw and skin biopsy
Description: The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood draw and skin biopsy
Description: The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood draw and skin biopsy
Description: The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.
Study: NCT06132464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanding Communication and Language Generated in Conversation Treatment
Description: ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
Study: NCT05924074

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological sampling
Description: The procedure will consist of an additional bone marrow sample and blood sample

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: The procedure will consist of an additional bone marrow sample and blood sample
Study: NCT05208879

Intervention type: BIOLOGICAL
Intervention: Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)
Description: Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up.

Intervention type: OTHER
Intervention: Characterization, evaluation and comparison of macular pigment density
Description: The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
Study: NCT06483087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated Education Program
Description: Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
Study: NCT06010745

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biotin and silicon
Description: The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Biotin and silicon
Description: The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert ingredients only
Study: NCT06236256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system
Description: The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MDI/CSII
Description: Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.